

Patient-derived Xenograft (PDX) Models Market
Scope: Industry Analysis, Market Size, Growth, Trends Till 2031
Request Sample Report
The Patient-derived Xenograft (PDX) Models market is experiencing significant growth, driven by advancements in personalized medicine. As of 2023, the market is valued at approximately $300 million, with increasing demand for effective cancer therapies. Key trends include enhanced model development and expanding applications in drug discovery and development. Request Sample Report
◍ Crown Bioscience
◍ Champions Oncology
◍ Wuxi Apptec
◍ The Jackson Laboratory
◍ EPO Berlin-Buch
◍ Oncodesign
◍ Xentech
◍ Envigo
◍ Charles River Laboratories
◍ Pharmatest Services
◍ Urosphere
◍ MEDICILON
◍ Horizon Discovery
◍ Shanghai Model Organisms Center
◍ GemPharmatech
◍ LIDE Biotech
The Patient-derived Xenograft (PDX) market features players like Crown Bioscience and Champions Oncology, which utilize PDX models for drug efficacy testing and biomarker discovery. Companies like Wuxi Apptec and Charles River Laboratories enhance therapeutic developments, driving market growth. Sales revenues include:
- Crown Bioscience: $50M+
- Champions Oncology: $30M+
- Charles River Laboratories: $2.5B+
Request Sample Report
Preclinical Drug development
Biomarker Analysis
Request Sample Report
Mouse Model
Rat Model
Request Sample Report
$ X Billion USD